Trials / Completed
CompletedNCT00770965
Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis
Phase II Single Dose, Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Study to Assess the Efficacy of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is an exploratory, 4 arm, parallel group, placebo-controlled study comparing three doses of AIN457 to placebo. Subjects with a diagnosis of moderate to severe chronic plaque psoriasis will be randomized to receive either AIN457 at one of the three doses studied or placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AIN457 | |
| BIOLOGICAL | Placebo |
Timeline
- Start date
- 2008-09-10
- Primary completion
- 2009-09-17
- Completion
- 2009-09-17
- First posted
- 2008-10-10
- Last updated
- 2018-03-12
- Results posted
- 2015-02-18
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00770965. Inclusion in this directory is not an endorsement.